"The voice for cancer physicians and their patients in Massachusetts."

New Indication: FDA approves blinatumomab for use in pediatric patients

01 Sep 2016 7:39 PM | Anonymous

On September 1st, 2016 the U.S. Food and Drug Administration approved BLINCYTO┬« (blinatumomab) for use in pediatric patients with relapsed or refractory Ph-negative B cell precursor Acute Lymphoblastic Leukemia. Read more. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software